

# Hirohisa Nakamae

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9194050/publications.pdf>

Version: 2024-02-01

172  
papers

4,326  
citations

257450

24  
h-index

118850

62  
g-index

184  
all docs

184  
docs citations

184  
times ranked

4592  
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 115, 77-86.	1.6	7
2	Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. <i>International Journal of Hematology</i> , 2022, 115, 33-42.	1.6	5
3	Effect of Donor NKG2D Polymorphism on Relapse after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 20.e1-20.e10.	1.2	2
4	Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 43-50.	2.4	5
5	Delayed immune-related neutropenia with hepatitis by pembrolizumab. <i>Immunotherapy</i> , 2022, 14, 101-105.	2.0	6
6	Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 115, 534-544.	1.6	5
7	Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 209.e1-209.e9.	1.2	5
8	High-Dose Chemotherapy With Autologous Stem Cell Transplantation in a Case of Refractory Peripheral T Cell Lymphoma With Tracheoesophageal Fistula: A Case Report. <i>Transplantation Proceedings</i> , 2022, 54, 189-192.	0.6	2
9	Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2022, , 1.	1.8	1
10	Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. <i>American Journal of Hematology</i> , 2022, 97, 780-790.	4.1	9
11	The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. <i>Hematological Oncology</i> , 2022, 40, 442-456.	1.7	3
12	Immunomodulatory and direct activities of ropeginterferon alfa-2b on cancer cells in mouse models of leukemia. <i>Cancer Science</i> , 2022, 113, 2246-2257.	3.9	2
13	Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 116, 744-753.	1.6	4
14	Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. <i>Bone Marrow Transplantation</i> , 2021, 56, 1126-1133.	2.4	27
15	Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 387-394.	2.4	13
16	Future strategies for HLA-haploidentical transplantation using high-dose cyclophosphamide. <i>Journal of Hematopoietic Cell Transplantation</i> , 2021, 10, 48-57.	0.1	0
17	Acute fibrinous and organizing pneumonia following hemophagocytic syndrome in two adult patients with hematological malignancies. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 61, 93-96.	0.8	1
18	Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 113, 840-850.	1.6	7

#	ARTICLE	IF	CITATIONS
19	Pretransplant plasma brain natriuretic peptide and N-terminal probrain natriuretic peptide are more useful prognostic markers of overall survival after allogeneic hematopoietic cell transplantation than echocardiography. <i>Bone Marrow Transplantation</i> , 2021, 56, 1467-1470.	2.4	1
20	Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 334.e1-334.e11.	1.2	23
21	Recurrence of Acute Lymphoblastic Leukemia with Bone Marrow Necrosis: A Case Report and Review of the Literature on the MRI Features of Bone Marrow Necrosis. <i>Internal Medicine</i> , 2021, 60, 1083-1088.	0.7	1
22	Risk Factor and Long-Term Outcome Analyses for Acute Limbic Encephalitis and Calcineurin Inhibitor-Induced Encephalopathy in Adults following Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 437.e1-437.e9.	1.2	2
23	Expression of activated integrin $\beta 7$ in multiple myeloma patients. <i>International Journal of Hematology</i> , 2021, 114, 3-7.	1.6	8
24	Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2510-2517.	2.4	9
25	Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapyâ€refractory or relapsed disease prior to allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 194, 403-413.	2.5	3
26	Increasing numbers of CD19 <sup>+</sup> CD24 <sup>high</sup> CD38 <sup>high</sup> regulatory B cells and pre-germinal center B cells reflect activated autoimmunity and predict future treatment response in patients with untreated immune thrombocytopenia. <i>International Journal of Hematology</i> , 2021, 114, 580-590.	1.6	3
27	Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy. <i>Frontiers in Immunology</i> , 2021, 12, 695037.	4.8	14
28	A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 928.e1-928.e7.	1.2	10
29	Tiny transformed diffuse large B cell lymphoma localized to the left conjunctiva. <i>International Journal of Hematology</i> , 2021, 114, 413-414.	1.6	0
30	Kinetics of IgG subclasses and their effects on the incidence of infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Immunology</i> , 2021, 67, 101413.	1.2	1
31	Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2021, 62, 3411-3419.	1.3	0
32	Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1005.e1-1005.e8.	1.2	1
33	Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade IIâ€IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group. <i>Annals of Hematology</i> , 2021, 100, 3029-3038.	1.8	5
34	Impact of HLA disparity on the risk of overall mortality in patients with grade IIâ€IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2990-2996.	2.4	2
35	Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. <i>Blood Advances</i> , 2021, 5, 4156-4166.	5.2	8
36	Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT. <i>Blood Advances</i> , 2021, 5, 475-486.	5.2	3

#	ARTICLE	IF	CITATIONS
37	Interactive Web Application for Plotting Personalized Prognosis Prediction Curves in Allogeneic Hematopoietic Cell Transplantation Using Machine Learning. <i>Transplantation</i> , 2021, 105, 1090-1096.	1.0	9
38	Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT. <i>JCI Insight</i> , 2021, 6, .	5.0	7
39	Isatuximab plus Pomalidomide and Dexamethasone in a Patient with Dialysis-Dependent Multiple Myeloma. <i>Chemotherapy</i> , 2021, 66, 1-4.	1.6	3
40	A Prospective Comparison Analysis of Blood Biomarkers for the Diagnosis and Prediction of Sinusoidal Obstruction Syndrome. <i>Blood</i> , 2021, 138, 2865-2865.	1.4	0
41	Cytomegalovirus Gastroenteritis in Patients with Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 3918-3918.	1.4	0
42	Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2021, , 1.	1.6	0
43	The Outcomes of Systemic Chronic Active EBV Infection Treatment By Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of Japanese Registry Data. <i>Blood</i> , 2021, 138, 3965-3965.	1.4	0
44	A noninvasive diagnostic approach using per-rectal portal scintigraphy for sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 470-472.	2.4	2
45	Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 722-728.	2.4	25
46	Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 307-315.	2.0	12
47	Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications: A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 66-75.	2.0	4
48	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for ATL with HTLV-1 Antibody-Positive Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 718-722.	2.0	3
49	Pretransplant serum beta $\alpha$ 2 microglobulin level is a potential novel prognostic marker of overall survival after allogeneic hematopoietic cell transplantation – a retrospective observational study. <i>Transplant International</i> , 2020, 33, 391-401.	1.6	1
50	Mosquito allergy: a novel strong prognostic symptom of outcome after allogeneic hematopoietic transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1509-1511.	2.4	0
51	Donor KIR2DS1-Mediated Decreased Relapse and Improved Survival Depending on Remission Status at HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 723-733.	2.0	7
52	Clinical usefulness of very high serum soluble interleukin-2 receptor levels for the detection of tuberculous peritonitis in a patient with chronic myelogenous leukemia. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 1054-1057.	1.7	2
53	Effect of Prophylactic Post-transplant Ponatinib Administration on Outcomes in Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 813-819.e1.	0.4	10
54	The critical role of CD4+ T cells in PD-1 blockade against MHC-II $\alpha$ -expressing tumors such as classic Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4069-4082.	5.2	76

#	ARTICLE	IF	CITATIONS
55	Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data. <i>Bone Marrow Transplantation</i> , 2020, 55, 2008-2016.	2.4	7
56	Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report. <i>BMC Infectious Diseases</i> , 2020, 20, 478.	2.9	10
57	Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e218-e225.	4.6	65
58	A high CD34+ cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 1726-1735.	2.4	10
59	Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by <i>Stenotrophomonas maltophilia</i> . <i>Internal Medicine</i> , 2020, 59, 193-198.	0.7	14
60	Acquired Gray Platelet Syndrome Associated with Primary Myelofibrosis. <i>Internal Medicine</i> , 2020, 59, 2751-2756.	0.7	0
61	Pretransplant Plasma Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Are More Useful Prognostic Markers of Overall Survival after Allogeneic Hematopoietic Cell Transplantation Than Echocardiography. <i>Blood</i> , 2020, 136, 38-39.	1.4	0
62	Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades. <i>Bone Marrow Transplantation</i> , 2019, 54, 578-586.	2.4	17
63	Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Philadelphia chromosome-positive ALL with minimal residual disease. <i>American Journal of Hematology</i> , 2019, 94, E301-E305.	4.1	1
64	Combination of Frailty Status and Comorbidity Score Improves the Stratification of Survival in Patients With Myelodysplastic Syndrome Owing to Good Predictive Capability for Infection-related Mortality. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 799-805.	0.4	17
65	Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer Science</i> , 2019, 110, 3255-3266.	3.9	32
66	A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors. <i>Transplant International</i> , 2019, 32, 1322-1332.	1.6	24
67	Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt). <i>International Journal of Hematology</i> , 2019, 110, 675-682.	1.6	19
68	Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients. <i>International Journal of Hematology</i> , 2019, 110, 736-742.	1.6	0
69	Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1327-1336.	2.4	7
70	Clinical Impacts of Using Serum IL-6 Level as an Indicator of Cytokine Release Syndrome after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2061-2069.	2.0	12
71	Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. <i>Bone Marrow Transplantation</i> , 2019, 54, 1789-1798.	2.4	39
72	Short-Term Fasting Induces Cell Cycle Arrest in Immature Hematopoietic Cells and Increases the Number of Naïve T Cells in the Bone Marrow of Mice. <i>Acta Haematologica</i> , 2019, 141, 189-198.	1.4	11

#	ARTICLE	IF	CITATIONS
73	Cytomegalovirus reactivation is associated with increased mortality more than 100%days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E143-E146.	4.1	8
74	Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. <i>Blood Advances</i> , 2019, 3, 105-115.	5.2	25
75	BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. <i>Blood Advances</i> , 2019, 3, 1750-1760.	5.2	6
76	The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission. <i>Transplantation</i> , 2019, 103, 2201-2210.	1.0	4
77	HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. <i>Haematologica</i> , 2019, 104, 1055-1061.	3.5	3
78	Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 2019, 109, 175-186.	1.6	14
79	Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis. <i>American Journal of Hematology</i> , 2019, 94, 103-110.	4.1	8
80	Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis. <i>Hematological Oncology</i> , 2019, 37, 85-95.	1.7	11
81	Current status of HLA haplo-identical transplantation using post-transplantation cyclophosphamide. <i>Journal of Hematopoietic Cell Transplantation</i> , 2019, 8, 16-21.	0.1	1
82	Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2019, 134, 4492-4492.	1.4	0
83	Impact of Donor KIR and HLA Genotypes on Clinical Outcomes According to Pre-Transplant Remission Status after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Blood</i> , 2019, 134, 2030-2030.	1.4	0
84	Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 353-360.e1.	0.4	89
85	Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial). <i>International Journal of Hematology</i> , 2018, 107, 535-540.	1.6	6
86	Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 717-725.	2.0	21
87	Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. <i>International Journal of Hematology</i> , 2018, 107, 327-336.	1.6	20
88	Impact of a Low CD34+ Cell Dose on Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 708-716.	2.0	13
89	Diagnostic value of serum ferritin and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation: methodological issues. <i>Leukemia and Lymphoma</i> , 2018, 59, 772-773.	1.3	0
90	The First Case of Non-leukemic Sarcoma Composed of Mixed-phenotype Acute Leukemia, B/myeloid, Not Otherwise Specified. <i>Internal Medicine</i> , 2018, 57, 1155-1158.	0.7	4

#	ARTICLE	IF	CITATIONS
91	Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). <i>Annals of Hematology</i> , 2018, 97, 2173-2183.	1.8	8
92	Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia. <i>European Journal of Haematology</i> , 2018, 101, 508-513.	2.2	10
93	Comparable Survival Outcomes of Haploidentical Stem Cell Transplantation and Unrelated Bone Marrow Transplantation. <i>Blood</i> , 2018, 132, 4644-4644.	1.4	1
94	Would Bone Marrow be Associated with Superior Outcomes Compared with Peripheral Blood for Male Recipients with Female Donors in HLA-Matched Related Transplantation?. <i>Blood</i> , 2018, 132, 4669-4669.	1.4	0
95	Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2000-2007.	2.4	10
96	Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study. <i>International Journal of Hematology</i> , 2017, 106, 385-397.	1.6	33
97	Diagnostic usefulness of plasma presepsin (soluble CD14-subtype) for diagnosing hemophagocytic syndrome in hematological malignancies. <i>Leukemia and Lymphoma</i> , 2017, 58, 2489-2492.	1.3	3
98	Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. <i>International Journal of Hematology</i> , 2017, 105, 792-804.	1.6	26
99	Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials. <i>International Journal of Hematology</i> , 2017, 105, 485-496.	1.6	6
100	Diagnostic value of serum ferritin and the risk factors and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 1664-1672.	1.3	15
101	Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. <i>American Journal of Hematology</i> , 2017, 92, 902-908.	4.1	14
102	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 75-80.	2.0	6
103	Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation. <i>International Journal of Hematology</i> , 2017, 105, 369-376.	1.6	8
104	Dasatinib and Prednisolone Induction Therapy for a Case of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Dilated Cardiomyopathy Accompanied by Life-Threatening Ventricular Tachycardia. <i>Case Reports in Hematology</i> , 2017, 2017, 1-4.	0.4	1
105	An Elderly Woman with Anti-neutrophil Antibody-positive Agranulocytosis Who Responded to High-dose Intravenous Methylprednisolone. <i>Internal Medicine</i> , 2017, 56, 2199-2203.	0.7	2
106	Lung function score including a parameter of small airway disease as a highly predictive indicator of survival after allogeneic hematopoietic cell transplantation. <i>Transplant International</i> , 2016, 29, 707-714.	1.6	11
107	Diagnostic value of levels of presepsin (soluble CD14-subtype) in febrile neutropenia in patients with hematological disorders. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 466-471.	1.7	20
108	Combinational approach using in situ hybridization targeting 23S ribosomal RNA genes and blood cultures for bacterial identification in patients with neutropenia and fever. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 697-703.	1.7	3

#	ARTICLE	IF	CITATIONS
109	Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosomeâ€“Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2208-2213.	2.0	29
110	Prognostic Effect of Low Subcutaneous Adipose Tissue on Survival Outcome in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 434-441.	0.4	39
111	Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale. <i>SpringerPlus</i> , 2016, 5, 569.	1.2	4
112	Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 423-431.	2.0	9
113	Combination of Frailty Status and Comorbidity Score Improves the Prediction of Survival in Patients with Myelodysplastic Syndrome Due to Good Predictive Capability for Infection-Related Mortality. <i>Blood</i> , 2016, 128, 1995-1995.	1.4	2
114	Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial. <i>Blood</i> , 2016, 128, 790-790.	1.4	22
115	Short-Term Fasting Induces Cell Cycle Arrest of Immature Hematopoietic Cells and Increases the Number of Naive T Cells in the Bone Marrow of Mice. <i>Blood</i> , 2016, 128, 5047-5047.	1.4	0
116	Safety and Efficacy of a Switch to Nilotinib in Patients with CML-CP Showing MMR to Imatinib: Results of a Multicenter Phase II Trial (NILSw Trial). <i>Blood</i> , 2016, 128, 1914-1914.	1.4	0
117	Prophylactic Use of a Combination of an Anticoagulant and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 5755-5755.	1.4	1
118	Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. <i>Blood</i> , 2015, 126, 415-422.	1.4	49
119	Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e528-e535.	4.6	261
120	Efficacy and safety of intra-arterial steroid infusions in patients with steroid-resistant gastrointestinal acute graft-versus-host disease. <i>Experimental Hematology</i> , 2015, 43, 995-1000.	0.4	6
121	Impact of HLA Mismatch Direction on the Outcome of Unrelated Bone Marrow Transplantation: A Retrospective Analysis from the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 305-311.	2.0	31
122	A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits. <i>International Journal of Hematology</i> , 2015, 102, 304-311.	1.6	16
123	Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin. <i>Experimental Hematology</i> , 2015, 43, 177-179.	0.4	15
124	Effect of Granulocyte Colonyâ€“Stimulating Factorâ€“Combined Conditioning in Cord Blood Transplantation for Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia: A Retrospective Study in Japan. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1632-1640.	2.0	16
125	Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2008-2016.	2.0	153
126	Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 2392-2397.	1.3	6



#	ARTICLE	IF	CITATIONS
127	HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome. <i>Experimental Hematology</i> , 2015, 43, 921-929.e1.	0.4	32
128	Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 3205-3205.	1.4	0
129	Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase. <i>Leukemia and Lymphoma</i> , 2014, 55, 2093-2100.	1.3	27
130	Diagnostic performance of serum high-sensitivity procalcitonin and serum C-reactive protein tests for detecting bacterial infection in febrile neutropenia. <i>Infection</i> , 2014, 42, 971-979.	4.7	22
131	Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. <i>International Journal of Hematology</i> , 2014, 99, 141-153.	1.6	27
132	Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia. <i>Blood</i> , 2014, 124, 3260-3260.	1.4	3
133	Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. <i>Blood</i> , 2014, 124, 4541-4541.	1.4	42
134	Effectiveness of Antibacterial Prophylaxis with Non-Absorbable Polymyxin B Compared to Levofloxacin after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1145-1145.	1.4	0
135	Ponatinib Safety and Efficacy in Japanese Patients with Philadelphia Positive Leukemia: Update of a Phase 1/2 Study. <i>Blood</i> , 2014, 124, 5541-5541.	1.4	0
136	Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia Transformed from Ph-Negative Myeloproliferative Neoplasm: A Study from the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). <i>Blood</i> , 2014, 124, 2547-2547.	1.4	0
137	The V50/V25 Ratio, a Marker of Small Airway Disease, Is Highly Predictive of Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 1208-1208.	1.4	0
138	A Detailed Analysis of Myelodysplastic Syndrome Complicated By Autoimmune or Inflammatory Disorders: A Possible Efficacy of Low-Dose Lenalidomide. <i>Blood</i> , 2014, 124, 3256-3256.	1.4	2
139	Odk-1201, One-Step RT-qPCR Major BCR-ABL/ABL mRNA Kit for the International Scale, with High Sensitivity to Detect Deeper MR. <i>Blood</i> , 2014, 124, 1805-1805.	1.4	0
140	Allogeneic Peripheral Blood Stem Cell Transplantation Using Reduced-Intensity Conditioning Regimen with Fludarabine and Busulfan from HLA-Matched Related Donor for Elderly Adult T-Cell Leukemia/Lymphoma: Results of Multicenter Phase II Study (ATL-NST-3). <i>Blood</i> , 2014, 124, 2580-2580.	1.4	0
141	Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial. <i>Blood</i> , 2013, 122, 3998-3998.	1.4	2
142	Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response. <i>Blood</i> , 2013, 122, 653-653.	1.4	24
143	ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes. <i>Blood</i> , 2013, 122, 92-92.	1.4	34
144	Diagnostic Value Of Serum Level Of Soluble CD14-Subtype In Febrile Neutropenia In Patients With Hematologic Disorders. <i>Blood</i> , 2013, 122, 4718-4718.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Cytomegalovirus Reactivation After Allogeneic Stem Cell Transplantation Is Associated With a Reduced Risk Of Relapse In Patients With Acute Myeloid Leukemia: The Japan Society For Hematopoietic Cell Transplantation (JSHCT) Transplantation-Related Complication Working Group. <i>Blood</i> , 2013, 122, 915-915.	1.4	0
146	HLA Haplo-Identical Peripheral Blood Stem Cell Transplantation Using High-Dose Cyclophosphamide Post-Transplantation For Poor Prognosis Or Refractory Acute Leukemia and Myelodysplastic Syndrome: A Prospective Pilot Study At a Single Center. <i>Blood</i> , 2013, 122, 3404-3404.	1.4	0
147	Gvhd Prophylaxis With Mycophenolate Mofetil and Calcineurin Inhibitor In Allogeneic Hematopoietic Cell Transplantation From HLA-Matched Siblings Or 7/8 HLA-Matched Unrelated Volunteer Donors: A Japanese, Multicenter, Phase II Trial. <i>Blood</i> , 2013, 122, 4586-4586.	1.4	0
148	Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. <i>Leukemia and Lymphoma</i> , 2012, 53, 1084-1089.	1.3	53
149	Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).. <i>Journal of Clinical Oncology</i> , 2012, 30, 6509-6509.	1.6	9
150	Tolerated, Low-Dose Deferasirox: Successful Three Cases of Aplastic Anemia and 34 Cases of MDS. <i>Blood</i> , 2012, 120, 1187-1187.	1.4	0
151	Prognostic Value for Survival of Serum Ferritin Levels Over Time After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 4466-4466.	1.4	0
152	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. <i>Lancet Oncology</i> , The, 2011, 12, 841-851.	10.7	444
153	Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation. <i>International Journal of Hematology</i> , 2011, 93, 509-516.	1.6	8
154	Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. <i>International Journal of Hematology</i> , 2011, 93, 624-632.	1.6	19
155	Immunoprofile of Patients with Chronic Myeloid Leukemia Treated with Imatinib, Nilotinib or Dasatinib,. <i>Blood</i> , 2011, 118, 3764-3764.	1.4	0
156	Risk Factors Affecting Cardiac Left Ventricular Systolic and Diastolic Function and Hypertrophy in the Chronic Phase Post-Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2011, 118, 2000-2000.	1.4	0
157	Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 362, 2260-2270.	27.0	1,411
158	Heart rate variability during and after peripheral blood stem cell leukapheresis in autologous transplant patients and allogeneic transplant donors. <i>International Journal of Hematology</i> , 2010, 91, 478-484.	1.6	3
159	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. <i>Blood</i> , 2010, 116, 2291-2291.	1.4	12
160	Dasatinib Compared with Imatinib In Newly Diagnosed Chronic Myelogenous Leukemia In Chronic Phase (CML-CP):Results of Japanese Subset Analysis In DASISION Trial.. <i>Blood</i> , 2010, 116, 4484-4484.	1.4	0
161	Factors That Contribute to Long-Term Survival In Patients with Leukemia Not In Remission at Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2010, 116, 3551-3551.	1.4	0
162	The Impact of Relative Dose Intensity (RDI) of CHOP on Outcome of Diffuse Large B-Cell Lymphoma: Results of a Single Center Study.. <i>Blood</i> , 2007, 110, 4456-4456.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2006, 81, 525-531.	4.1	99
164	Reduced Intensity Conditioning (RIC) with Cladribine, Busulfan and 4 Gy Total Body Irradiation (TBI) for Bone Marrow Transplantation (BMT) from an HLA-Matched Unrelated Donor (URD): A Prospective Multi-Institutional Clinical Trial.. <i>Blood</i> , 2006, 108, 5397-5397.	1.4	2
165	Chronic Myeloid Leukemia in Two Patients with Gastrointestinal Stromal Tumor.. <i>Blood</i> , 2006, 108, 4767-4767.	1.4	0
166	Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. <i>Cancer</i> , 2005, 104, 2492-2498.	4.1	210
167	Conditioning Regimens Including High-Dose Busulfan Cause a High Incidence of Transplant-Related Mortality after Myeloablative Stem Cell Transplantation. <i>Chemotherapy</i> , 2004, 50, 178-183.	1.6	1
168	Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2004, 76, 1-7.	4.1	33
169	QT Dispersion Correlates with Systolic Rather than Diastolic Parameters in Patients Receiving Anthracycline Treatment. <i>Internal Medicine</i> , 2004, 43, 379-387.	0.7	23
170	Significant and Morbid Changes in Heart Rate Variability Precedes and Complicates Symptomatic Hypotension in Peripheral Blood Stem Cell Apheresis.. <i>Blood</i> , 2004, 104, 4996-4996.	1.4	0
171	QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. <i>Lancet, The</i> , 2000, 355, 805-806.	13.7	56
172	A Case of Rhabdomyolysis due to Levofloxacin. <i>Clinical Drug Investigation</i> , 2000, 20, 203-205.	2.2	10